Enveda

?? We did it again! For the 2nd year in a row, Enveda has been named one of America’s Best Startup Employers – and we’re ranked #2 in biotech! ? ?? https://lnkd.in/dGSX3ahr This recognition is a reflection of the incredible people who make Enveda a bold, mission-driven company where innovation thrives. If you’re ready to do the most impactful work of your career and be part of a once-in-a-generation company that’s transforming the future of medicine, we’d love to meet you. Come build with us! #hiring #biotech #startup #bestemployers

In case you missed the largest gathering in tech last month, our CEO and Founder Viswa Colluru, PhD discussed the future of AI and healthcare. "AI matches, recognizes and generates patterns and it will help move medical science forward..." watch here: https://lnkd.in/gNaqBVhu #WebSummitQatar #biotech #AI #innovation

We're #hiring a new Asst. VP, Biology in Hyderabad, Telangana. Apply today or share this post with your network.

We're #hiring a new Principal Scientist, Computational Biology in Boulder, Colorado. Apply today or share this post with your network.

?? We’ve been backed by leading investors behind SpaceX, Amazon, and other world-changing companies, and now we’re adding one of the biggest names in #pharma to our list. Today, we’re excited to share that Sanofi has joined our Series C syndicate, bringing the total raise to $150M! Our platform leverages #AI to sequence #lifeschemistry and beats industry averages for #drugdiscovery across time, cost, and outcomes. We’re just getting started. We have several more clinical trials set to start this year… stay tuned! ?? Read more: https://lnkd.in/gexDr2Qt #biotech #innovation #learningfromlife

We are standing at the edge of a new era—one where technology’s impact on humanity is more profound than ever before. At Enveda, we’re pioneering the use of AI to explore the vast 99.9% of unknown chemistry that defines life, unlocking new possibilities for medicine and beyond. Breakthroughs don't happen in isolation—it’s through collaboration, curiosity, and bold ideas that we push the boundaries of what’s possible. That’s why we’re excited to share our journey and progress at Web Summit Qatar, where the world’s brightest minds come together to build the future. Let’s make it happen!??? Our CEO and Founder Viswa Colluru, PhD will be speaking on the Center Stage: February 25, 12:00 - 12:20pm? How AI is physiologically changing humans? https://lnkd.in/gRrc2V89 #WebSummitQatar #biotech #AI #innovation

Despite the high prevalence of #asthma and >1.6M asthma-related ER visits every year, no new oral asthma drugs have been approved in over two decades. That's why we are excited to advance ENV-294. ENV-294 could transform asthma treatment, offering a first-in-class therapy that can be used long-term. “ENV-294 has the potential to redefine asthma treatment by targeting key pathways involved in airway inflammation via a non-steroidal, orally delivered therapeutic,” said Viswa Colluru, PhD, CEO and Founder of Enveda. “We are thrilled to be working with a distinguished group of scientific and clinical leaders to guide our efforts in bringing this innovative therapy to patients.” Read more: https://lnkd.in/gnidCSDN #biotech #AI #innovation?

Thanks?NYSE?for including Enveda in these vital conversations about the future of health, including the role of artificial intelligence in shaping that future. In part 2 of the Cure(ious) series, our CEO and Founder, Viswa Colluru, PhD shares how AI and our ability to scale a shared expertise and collective knowledge will be critical to meet patient needs. Watch here:?https://lnkd.in/eFAXna7R Enveda is leveraging AI to deterministically and quickly tap into nature's chemistry to develop innovative medicines faster. #biotech #AI #innovation #futureofhealthcare

We're #hiring a new Paralegal in Boulder, Colorado. Apply today or share this post with your network.

ENV-294 is more than just a new approach—it represents hope for those struggling with the daily burden of #asthma. By leveraging nature's chemistry through our platform, we are committed to transforming patient outcomes and reshaping the future of Inflammation & Immunology. Michael Wechsler, MD MMSc, Chair of our Asthma Advisory Board, has spent a career at the forefront of treating this disease and captures our vision perfectly: "Asthma remains a challenging disease with significant unmet needs, and ENV-294's novel mechanism of action and safe oral administration has the potential to change the treatment paradigm for many patients." At Enveda, we believe in taking bold new approaches and learning from life to renew life.